Study Findings: Testosterone and Triple Negative Breast Cancer - Mayo Clinic

Could blocking an androgen ( testosterone) receptor lead to a new way to treat an aggressive form of breast cancer?

That's a question researchers at the Mayo Clinic in Arizona and the Translational Genomics Research Institute (TGen) in Phoenix, AZ are exploring. Preliminary results of a Mayo Clinic -- TGen collaborative study show the androgen receptor may be a potential target to attack in treating triple negative breast cancer (TNBC).

Barbara Pockaj, M.D., a surgical oncologist at the Mayo Clinic in Arizona, discusses the study findings and the next steps in research.